论文部分内容阅读
目的探讨骨代谢指标血清骨钙素(GBP)、Ⅰ型胶原羧基末端肽(ICTP)和尿羟脯氨酸(uHOP)早期诊断乳腺癌骨转移的应用价值。方法对86例原发性乳腺癌和20例正常女性分别采用放射免疫法测定血清BGP、ICTP和uHOP,用ECT核素骨扫描确定乳腺癌有无骨转移。结果无骨转移乳腺癌患者与正常人之间血清BGP、ICTP和uHOP水平差异无统计学意义(P>0.05),随访2年中32例血清BGP、ICTP和UHOP水平升高,其中29例平均在3个月后ECT核素骨扫描示骨转移,骨转移后血清BGP、ICTP和uHOP水平较转移前明显升高(P<0.01)。结论血清GBP、ICTP和uHOP在乳腺癌骨转移的早期诊断方面有重要应用价值,且能比ECT核素骨扫描较早发现骨转移。
Objective To investigate the value of bone metabolism index serum osteocalcin (GBP), type Ⅰ collagen carboxyl terminal peptide (ICTP) and urinary hydroxyproline (uHOP) in the early diagnosis of bone metastasis of breast cancer. Methods Serum BGP, ICTP and uHOP were measured by radioimmunoassay in 86 cases of primary breast cancer and 20 cases of normal women. The bone metastasis of breast cancer was determined by ECT nuclide bone scan. Results There was no significant difference in serum BGP, ICTP and uHOP levels between patients with and without bone metastasis (P> 0.05). Serum levels of BGP, ICTP and UHOP increased in 32 patients After three months, the levels of serum BGP, ICTP and uHOP in ECT nuclide bone scaffolds were significantly higher than those before metastasis (P <0.01). Conclusion Serum GBP, ICTP and uHOP have important value in the early diagnosis of bone metastasis of breast cancer, and they can detect bone metastasis earlier than that of ECT nuclide bone scan.